All

AI Model Enhances Prognostic Accuracy with Multi-Omics Integration

MULGONET, a novel multi-omics framework, improves tumor recurrence prediction by integrating gene ontology-guided architecture.

All

New Tech Illuminates Bladder Cancer Detection

New technology detects bladder cancer in both the clinic and operating room settings by using blue and white light, and an imaging dye.

All

COVID-19 Delayed Cancer Treatment, Diagnoses

Restrictions in access to care during the COVID-19 pandemic caused disruptions in the treatment and diagnoses of cancer and other conditions.

Novel Urine Screening Test Can Detect New and Recurrent Bladder Cancer

Jun 4, 2021 | Unknown Origin & Other Cancer Types

A study found a new urine screening test using a novel K17 cancer biomarker can detect new bladder cancer in patients with blood in the urine.

Urine Protein Biomarkers May Have Diagnostic Potential

May 24, 2021 | Unknown Origin & Other Cancer Types

Researchers have identified urine protein biomarkers of bladder cancer. ELISA validation was used to validate the top four biomarkers.

Decipher Identifies Bladder Cancer Patients Most Likely to Benefit from Neoadjuvant Immunotherapy

May 7, 2020 | Unknown Origin & Other Cancer Types

Patients with muscle-invasive bladder cancer who had the molecular subtype basal claudin low received the greatest benefit from Keytruda immunotherapy.

miR Scientific Introduces Sentinel Disease Management Platform

Mar 24, 2020 | Cancer, Molecular Diagnostics, Unknown Origin & Other Cancer Types

The Sentinel disease management platform incorporates a number of noninvasive liquid biopsy urine tests that can help accurately detect, score, and monitor urological cancers.

Pangea Licenses At-Home Urine Test for Bladder Cancer Detection

Mar 8, 2019 | Research

The test features a noninvasive, epigenetic-based option for collection at home or in a doctor’s office.

GenomeDx Biosciences Launches Bladder Cancer Assay

Jun 26, 2017 | Cancer, Unknown Origin & Other Cancer Types

The company has commercially released the Decipher bladder cancer classifier following publication of a study supporting its development and validation.

Bladder Cancer Monitor Addresses Cancer Recurrence

Dec 13, 2016 | Cancer, Molecular Diagnostics, Unknown Origin & Other Cancer Types

The Cepheid test is now commercially available in Germany and cleared for commercial availability in all countries accepting the CE mark.

Gene Expression Signature Predicts Lymph Node Metastasis in Bladder Cancer

Jul 18, 2016 | Research

The Decipher GRID platform was recently used to develop and validate KNN51 for the prediction of lymph node involvement at the time of radical cystectomy in patients with muscle-invasive bladder cancer.

Grant Supports Outcomes Research for Noninvasive Genomic Profiling

Apr 1, 2016 | Research

Affymetrix has received funding to investigate the value of its formalin-fixed, paraffin-embedded assay kit for patients with non-muscle invasive bladder cancer.